Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
VMAT2 inhibitors
17 evidence topics · 17 sources
EHDN international guideline: first-line treatment of chorea
AAN evidence-based guideline on chorea (retired 2022): recommendation
“If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit. Occurrence of adverse events should be discussed and monitored, particularly depression/suicidality and parkinsonism with tetrabenazine and elevated liver enzymes with riluzole.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German Neurological Society guideline: evidence for VMAT2 inhibitors and use of tetrabenazine
“The quality of data from RCTs is currently best for VMAT2 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of tetrabenazine (in combination or as monotherapy) is recommended if treatment with tiapride is either not tolerated or not efficacious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MDS evidence-based review of treatments for Huntington's disease
“These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cochrane review of symptomatic treatments
“22 trials (1254 participants) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only tetrabenazine showed a clear efficacy for the control of chorea. The remaining pharmacological interventions revealed no clear effectiveness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HSG expert consensus: classes used for chorea in North American practice
“Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tetrabenazine: FDA-approved indication and boxed warning
Tetrabenazine: label efficacy and functional outcomes in Study 1
Tetrabenazine: depression and sedation in the placebo-controlled trial
Tetrabenazine: TETRA-HD randomized trial
“The authors randomized 84 ambulatory patients with HD to receive TBZ (n = 54) or placebo (n = 30) for 12 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were five study withdrawals in the TBZ group and five serious adverse events (SAEs) in four subjects (drowning suicide, complicated fall, restlessness/suicidal ideation, and breast cancer) compared with one withdrawal and no SAEs in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deutetrabenazine: FDA boxed warning and label efficacy
Deutetrabenazine: First-HD randomized trial
“Treatment success, as measured by the PGIC, occurred in 23 patients (51%) in the deutetrabenazine group vs 9 (20%) in the placebo group (P = .002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Valbenazine: FDA boxed warning and label efficacy
Valbenazine: parkinsonism in Huntington's disease
Valbenazine: KINECT-HD randomized trial
“Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No suicidal behaviour or worsening of suicidal ideation was reported in participants treated with valbenazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote